IRD (Opus Genetics) Valuation Rank


IRD Opus Genetics Inc IRD
24 GF Score
Price $3.66
GF Value $0.37
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Opus Genetics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Opus Genetics Valuation Rank Related Terms

IRD
24GF Score
Opus Genetics Inc IRD
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $3.66 is trading 887.8% above its estimated GF Value™ of $0.37. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

  • Valuation Rank:
  • GF Value™: $0.37 vs. price of $3.66 (887.8% above fair value)
  • GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Other Exchanges R3X1:Germany
Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
24GF Score

Get the complete analysis for IRD

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.66
Price
$0.37
GF Value